Interestingly, these data have been recently confirmed in a large population-based cohort of RA patients demonstrating that abatacept was associated with a significant 29% reduced risk of a CV composite endopoint (myocardial infarction, stroke/transient ischemic attack, and coronary revascularization) when compared with TNFα-i therapy, in particular in patients with diabetes mellitus (58). The gene discussed is TNF; the disease is stroke disorder.